Clinical Trial Update: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating nivolumab in combination with ipilimumab for advanced hepatocellular carcinoma is ongoing (active, not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING